Literature DB >> 32476954

Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis.

Misbah Baqir1, Eunhee E Yi2, Thomas V Colby3, Christian W Cox4, Jay H Ryu1, Ulrich Specks1.   

Abstract

Background: The association between interstitial lung disease (ILD) and myeloperoxidase (MPO)-antineutrophil cytoplasmic antibodies (ANCAs) has been described, but pathologic characteristics are not well characterized.
Objectives: We assessed the radiologic and pathologic characteristics of ILD in MPO-ANCA-positive patients and the association between ILD and vasculitis, particularly microscopic polyangiitis (MPA).
Methods: We retrospectively searched electronic health records to identify MPO-ANCA-positive patients with ILD who underwent surgical lung biopsy at our institution from January 1997 through August 2017. Demographic, clinical, imaging, and pathologic characteristics were analyzed.
Results: We identified 18 MPO-ANCA-positive patients with ILD. The median (range) age was 58 (43-75) years, and the cohort included 10 men (56%), 10 former smokers (56%), and 11 patients (61%) had clinical evidence of systemic vasculitis (MPA) at the time of diagnosis of ILD. On high-resolution computed tomography, the most common radiologic pattern was "inconsistent with usual interstitial pneumonia" (UIP) (n=14 [78%]); the other 4 patients (22%) fulfilled the radiologic criteria for the UIP pattern. Honeycombing was seen in 15 patients (83%). Ten patients (56%) had the UIP pattern on biopsy: 4 of these patients had additional inflammatory changes that were not typical of UIP (as seen in patients with idiopathic pulmonary fibrosis), and the other 6 patients had other inflammatory patterns or findings. The presence or absence of MPA did not correlate with pathologic findings. Conclusions: MPO-ANCA-positive patients with ILD do not show the typical UIP pattern as seen in patients with idiopathic pulmonary fibrosis on surgical lung biopsy. Copyright:
© 2020.

Entities:  

Keywords:  ILD; UIP; interstitial lung disease; microscopic polyangiitis; myeloperoxidase antibodies; usual interstitial pneumonia

Mesh:

Substances:

Year:  2019        PMID: 32476954      PMCID: PMC7247085          DOI: 10.36141/svdld.v36i3.8053

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  19 in total

1.  The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis.

Authors:  Hassan F Nadrous; Patricia A Pellikka; Michael J Krowka; Karen L Swanson; Nithima Chaowalit; Paul A Decker; Jay H Ryu
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis.

Authors:  Masaru Ando; Eishi Miyazaki; Toshihiro Ishii; Yutaka Mukai; Mari Yamasue; Hideaki Fujisaki; Takeo Ito; Shin-ichi Nureki; Toshihide Kumamoto
Journal:  Respir Med       Date:  2013-02-19       Impact factor: 3.415

4.  Microscopic polyangiitis associated with pulmonary fibrosis.

Authors:  Marcelo Fernandez Casares; Alejandra Gonzalez; Mariano Fielli; Flavia Caputo; Yanina Bottinelli; Marcelo Zamboni
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

5.  A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients.

Authors:  Tomoko Nozu; Mitsuko Kondo; Kazuo Suzuki; Jun Tamaoki; Atsushi Nagai
Journal:  Respiration       Date:  2008-12-11       Impact factor: 3.580

6.  Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis.

Authors:  G E Tzelepis; M Kokosi; A Tzioufas; S P Toya; K A Boki; A Zormpala; H M Moutsopoulos
Journal:  Eur Respir J       Date:  2009-11-19       Impact factor: 16.671

7.  Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Sakae Homma; Hiroshi Matsushita; Koichiro Nakata
Journal:  Respirology       Date:  2004-06       Impact factor: 6.424

Review 8.  Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature.

Authors:  Cloé Comarmond; Bruno Crestani; Abdellatif Tazi; Baptiste Hervier; Sylvain Adam-Marchand; Hilario Nunes; Fleur Cohen-Aubart; Marie Wislez; Jacques Cadranel; Bruno Housset; Célia Lloret-Linares; Pascal Sève; Christian Pagnoux; Sébastien Abad; Juliette Camuset; Boris Bienvenu; Michaël Duruisseaux; Eric Hachulla; Jean-Benoît Arlet; Mohammed Hamidou; Alfred Mahr; Matthieu Resche-Rigon; Anne-Laure Brun; Philippe Grenier; Patrice Cacoub; David Saadoun
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

9.  Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis.

Authors:  Naho Kagiyama; Noboru Takayanagi; Tetsu Kanauchi; Takashi Ishiguro; Tsutomu Yanagisawa; Yutaka Sugita
Journal:  BMJ Open Respir Res       Date:  2015-01-09

10.  A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China.

Authors:  Hui Huang; Yan Xun Wang; Chun Guo Jiang; Jia Liu; Ji Li; Kai Xu; Zuo Jun Xu
Journal:  BMC Pulm Med       Date:  2014-01-28       Impact factor: 3.317

View more
  5 in total

1.  Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease.

Authors:  Koichi Yamaguchi; Aya Yamaguchi; Masashi Ito; Ikuo Wakamatsu; Miki Itai; Sohei Muto; Shogo Uno; Masaki Aikawa; Shunichi Kouno; Masao Takemura; Masakiyo Yatomi; Haruka Aoki-Saito; Yasuhiko Koga; Kenichiro Hara; Shinsuke Motegi; Mayuko Tsukida; Fumie Ota; Yoshito Tsukada; Mitsuru Motegi; Masao Nakasatomi; Toru Sakairi; Hidekazu Ikeuchi; Yoriaki Kaneko; Keiju Hiromura; Toshitaka Maeno
Journal:  Clin Rheumatol       Date:  2022-10-04       Impact factor: 3.650

Review 2.  Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Authors:  Hideaki Yamakawa; Yuko Toyoda; Tomohisa Baba; Tomoo Kishaba; Taiki Fukuda; Tamiko Takemura; Kazuyoshi Kuwano
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

3.  Original Article: Clinical Research.

Authors:  Gulay Dasdemir Ilkhan; Fatma Demirci Üçsular; Hakan Celikhisar; Yücel Arman; Enver Yalnız; Tufan Tükek
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-06-28       Impact factor: 0.670

4.  Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease.

Authors:  Lee M Fidler; Sonja Kandel; Jolene H Fisher; Shikha Mittoo; Shane Shapera
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-06-28       Impact factor: 0.670

Review 5.  MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives.

Authors:  Masashi Bando; Sakae Homma; Masayoshi Harigai
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 1.803

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.